Product
소개
EnbrBridge Elisa For Enbrel biosimilar comparison
Complete kit for the systematic 3-D conformational comparability analysis of
Enbrel biosimilar molecule to Etanercept (Enbrel trade name)
Etanercept (trade name Enbrel) is a biopharmaceutical that treats autoimmune disease by acting as a
TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile rheumatoid arthritis
and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.Etanercept is a fusion protein
produced by recombinant DNA, fusing the TNF receptor to the constant region of the IgG1 antibody.
Etanercept is a large molecule, with a molecular weight of 150 kDa., that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases and potentially in a variety of other disorders mediated by excess TNFα.
주문정보
관련자료